Christine Pratilas

Medicine & Life Sciences

1. Mitogen-Activated Protein Kinase Kinases 100%
2. Neurofibrosarcoma 81%
3. Neoplasms 54%
4. Mutation 41%
5. Neurofibromatosis 1 37%
6. Sarcoma 36%
7. Pediatrics 26%
8. Melanoma 23%
9. Desmoplastic Small Round Cell Tumor 21%
10. Young Adult 20%
11. Plexiform Neurofibroma 18%
12. Ewing's Sarcoma 18%
13. Therapeutics 17%
14. Cell Line 16%
15. Wilms Tumor 15%
16. WZ4002 15%
17. Receptor Protein-Tyrosine Kinases 15%
18. AZD 6244 13%
19. Neoplasm Metastasis 13%
20. Glioma 13%
21. Telomere Homeostasis 13%
22. Neurofibroma 12%
23. Growth 12%
24. Prenylation 12%
25. dabrafenib 12%
26. Heterografts 11%
27. Pharmaceutical Preparations 11%
28. Child 11%
29. rho GTP-Binding Proteins 11%
30. Rhabdomyosarcoma 10%
31. Extracellular Signal-Regulated MAP Kinases 10%
32. Vemurafenib 10%
33. Gene Fusion 9%
34. entrectinib 9%
35. Nerve Sheath Neoplasms 9%
36. ErbB Receptors 9%
37. Oncogenes 8%
38. Lung 8%
39. Survival 8%
40. Genes 8%
41. Chromosomes, Human, Pair 8 8%
42. 7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile 8%
43. Adenoma 8%
44. Brain Neoplasms 8%
45. Mitogen-Activated Protein Kinases 8%
46. Carcinogenesis 8%
47. Radiation 7%
48. MAP Kinase Signaling System 7%
49. Referral and Consultation 7%
50. Physiological Feedback 7%